News >

UK Expands Olaparib Maintenance Indication in Ovarian Cancer

Gina Columbus
Published: Tuesday, Dec 03, 2019

The UK’s National Institute for Health and Care Excellence has approved olaparib (Lynparza) for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.1

Before this expanded indication, olaparib was available as a capsule formulation within NHS England and Wales via routine commissioning for patients with relapsed BRCA-mutant ovarian cancer who had received ≥3 lines of chemotherapy. With the updated indication, olaparib is now available as a tablet formulation for these patients, as well as for patients within NHS England via the Cancer Drugs Fund (CDF) if they have had 2 courses of platinum-based chemotherapy.

The new indication is based on findings from the phase III SOLO2 and the phase II Study 19 trials. SOLO2 showed a clinically meaningful and statistically significant improvement in progression-free survival (PFS) at 19.1 months with olaparib compared with 5.5 months with placebo (HR, 0.30; 95% CI, 0.22-0.41; P <.0001) via investigator assessment. The estimated 2-year PFS rates were 43% and 15%, respectively.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication